chevron_leftBack
As of 24 April 2025, Hubei Biocause Pharmaceutical Co., Ltd. has a market cap of $2.38B USD, ranking #4766 globally and #989 in China. It ranks #738 in the Financial Services sector, and #47 in the Insurance - Life industry.
Key Stats
Market Cap
$2.38BUSD
17.34B CNY
Enterprise Value
$5.59BUSD
40.77B CNY
Revenue (TTM)
$5.59BUSD
40.7B CNY
EBITDA (TTM)
-$279.67MUSD
-2.04B CNY
Net Income (TTM)
-$105.92MUSD
-771.87M CNY
EBITDA Margin
-5%
Profit Margin
-1.9%
Company Profile
Country (HQ)
Sector
Financial Services
Industry
Insurance - Life
CEO
Wenxia Zhou
open_in_new
Employees
1,765
Website
biocause.com/
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.9% | -2.8% | -10% | -11% | 5.7% | 56% |
Upcoming Earnings
Earnings Date
Tue, Apr 29
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
000627
天茂实业集团股份有限公司 Class A
ISIN: CNE000000F48
Shares Out.:
Shares Outstanding:
4.553B1
Shares Float:
1.801B2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3.51 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Hubei Biocause Pharmaceutical Co., Ltd.
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.
